Alexander Maxwell
Value, growth, long-term horizon, biotech

Flamel Technologies: An Interesting Long-Term Investment

Flamel Technologies (NASDAQ:FLML) has had a string of rather good news. It recently received FDA approval for its drug Bloxiverz. What is even better is the fact that Flamel already has a rather substantial amount of income coming in for a small-cap stock. With all of this good news, there is still a large amount of upside potential left for this stock. The one main problem with Flamel Technologies is in the fact that it is hesitant to report key information about its drugs in development. This makes planning for the long term to be much more of a guessing game than usual (which is already a huge guessing game). However, this represents interesting catalysts depending on...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details